Capricor’s Deramiocel faces FDA decision on Nov 22 after award and data submission
+1 new source since this summary was written
Capricor Therapeutics (CAPR) said the FDA moved its decision on the Deramiocel gene therapy to Nov 22 after the company submitted additional HOPE‑3 trial analyses. The company highlighted that the trial met its primary goal, delivering a 1.1‑point gain in arm‑hand function, and noted that the drug recently earned an American Heart Association pediatric cardiology award. Investors are watching the upcoming regulatory verdict and the firm’s third‑quarter earnings call.
Why it matters
The FDA’s final review date determines whether the drug can reach market, which would affect CAPR’s revenue potential and cash runway; the company’s Q3 loss of $42.7 million and $198.5 million cash balance set the financial context for the decision.
Key facts
- 1The FDA postponed its decision on Deramiocel to Nov 22 after Capricor provided extra 24‑month HOPE‑3 data. finance.yahoo.com
- 2The HOPE‑3 trial achieved its primary endpoint, showing a 1.1‑point improvement in upper‑limb function. finance.yahoo.com
- 3Deramiocel’s data won an American Heart Association pediatric cardiology research award. stocktwits.com
- 4Capricor reported a third‑quarter net loss of $42.7 million. finance.yahoo.com
- 5The company held $198.5 million in cash, equivalents and marketable securities at quarter‑end. finance.yahoo.com
- 6Analysts expect Q3 revenue of $10.4 million and a loss of $0.42 per share. stocktwits.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.